Insulin glargine (Basaglar)
Peptide
Also known as LY2963016
Evidence outlook
Approved: Type 2 Diabetes, Type 1 Diabetes
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Adults with type 1 or type 2 diabetes (subsequent entry biologic to Lantus); pediatric type 1
- Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ELEMENT 2 NCT01421459 · Diabetes Mellitus, Type 2 The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin. Registry: NCT01421459 | 3 | Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, Endpoint (up to 24 weeks)) 2012-09 | Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, Endpoint (up to 24 weeks)): LY2963016 + OAMs -1.286 percentage of glycosylated hemoglobin (Standard Error 0.06) vs Lantus + OAMs -1.338 percentage of glycosylated hemoglobin (Standard Error 0.06) | Partial signal | link ↗ |
View 2 more trials
ELEMENT 5 NCT02302716 · Diabetes Mellitus, Type 2 Participants were randomly assigned to LY2963016 or active treatment with Lantus, with 249 and 244 participants respectively, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority margin, while the surrogate nature of HbA1c and open-label design support a moderate evidence grade. Registry: NCT02302716 | 3 | Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks) 2016-07 | Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067) | Partial signal | link ↗ |
NCT03338010 NCT03338010 · Type 2 Diabetes The study randomized 536 participants to LY2963016 or active-control Lantus® but was not blinded. Its primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a surrogate measure rather than a hard clinical endpoint, supporting a moderate evidence grade. Registry: NCT03338010 | 3 | Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24) 2020-03-18 | Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 4 (1)
What this study did
Competitive landscape
Other Insulin receptor (basal) drugs
insulin degludec, insulin detemir, Insulin Efsitora Alfa, insulin glargine, Insulin glargine (Toujeo) and 7 more. Compare all 13 Insulin receptor (basal) drugs
This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Insulin Glargine (Basaglar): this drug | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Afrezza | Approved | Peptide | Insulin | Partial signal | NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis). | |
| Insulin Aspart (NovoLog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Aspart (Fiasp) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Detemir (Levemir) | ApprovedUS marketing discontinued | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Lantus) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glargine (Toujeo) | Approved | Peptide | Insulin receptor (basal) | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Human | Approved | — | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Humalog) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin Lispro (Lyumjev) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Insulin NPH (Humulin N) | Approved | Peptide | Insulin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pramlintide (Symlin) | ApprovedUS marketing discontinued | Peptide | Amylin receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cadisegliatin | Phase 3 | Small molecule | Glucokinase | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zimislecel | Phase 3 | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacement | not yet graded | No reviewed efficacy summary in this indication | |
| Icovamenib | Phase 2 | Small molecule | Menin | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
6 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.